SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

Date of Report: October 10, 2011

(Date of earliest event reported)

XECHEM INTERNATIONAL, INC.

(Exact name of registrant as specified in the charter)

Delaware	0-23788	22-3284403
(State or other jurisdiction of incorporation)	(Commission File No.)	(IRS Employer Identification No.)

~~Xechem International~~1550 Main Street, ~~Inc.~~Suite A3

~~PO Box~~Windsor, ~~327~~CO 80550

~~Middletown, NJ 07748-0327~~(Address of Principal Executive Offices)

(~~732~~970) ~~247~~377-~~3300~~ 9554

Registrant’s telephone number including area code)

~~NOT~~New ~~APPLICABLE~~Brunswick Technology Center

100 Jersey Avenue, Building B, Suite 310

New Brunswick, New Jersey 08901-3279

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o£ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o£ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o£ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~ Section 8~~.01~~ - Other Events.

~~The Company~~Item ~~filed~~8.01 ~~the~~Other ~~following self explanatory letter with the Securities and Exchange Fraud Enforcement Division on July 10, 2009:~~Events

~~Xechem International,~~Change ~~Inc. ("Company") is a public company. It has come to our attention that Dr. Ramesh Pandey, CEO~~ of ~~the~~trading Company from the time it went public in 1994 until his removal in July 2007, may have filed fraudulent SEC documents. SEC documents filed and signed by Dr. Pandey indicate that Xechem International owns 2/3 of Xechem India Pvt, Ltd. (“XIndia”) as shown by the following statement from the 10QSB filed in 2007, “(c) Xechem India is presently owned 66-2/3% by the Company and the remainder by Ramesh C. Pandey and family members”. It was discovered in 2007 that XIndia is nearly 100% owned by Mr. Pandey and this was reported to the SEC. The Company sent over $1 million to XIndia since 2000, which was used to buy land owned by XIndia, pay employees, including members of Dr. Pandey’s family and other uses. It was thought this situation could be resolved, however, as of July 10, 2009, the Company still does not have 2/3 ownership of XIndia per SEC filings.Symbol

On ~~another~~ ~~matter~~October 7, Dr2011, the ‘Q’ was removed from the trading symbol of XKEMQ.PK ~~Pandey~~changing ~~filed~~it ato ~~10QSB~~XKEM.PK. The ~~and~~"Q" adesignation ~~S3/A~~is ~~dated~~used ~~8/14/02~~to ~~and~~indicate ~~10/19/02~~reorganization under the Bankruptcy Code. On August 24, ~~respectively~~ 2011, ~~stating~~all ~~that~~right, atitle, ~~drug~~and ~~(NIPRISAN)~~interest ~~licensed~~to byany and all assets of Xechem International, Inc. (the “Company”) ~~from~~and ~~the National~~Xechem, ~~Institute~~Inc. ofwhere ~~Pharmaceutical~~sold ~~Research~~at auction, including any and ~~Development~~all right, title and interest to Xechem (~~NIPRD~~India) ~~in Nigeria,~~Pvt. ~~was~~Limited ~~patented~~and inXechem 46Pharmaceuticals ~~countries~~Nigeria Limited. ~~This~~For ~~was~~further ininformation, ~~accordance~~see ~~with the~~case ~~statements~~no. 08-30512 in the ~~NIPRD~~United ~~license~~States ~~agreement~~Bankruptcy ~~signed~~Court, inNorthern ~~July~~District ~~2002~~of Illinois (Eastern Division).

~~NIPRISAN has~~Xechem ~~been~~International, ~~a major asset of the Company since 2002~~Inc. ~~The~~ ~~Company has invested millions of dollars in Nigeria since July 2003~~ and ~~investors~~Ministry ~~relied on the statements found in the SEC filings~~ of ~~NIPRISAN~~Health, ~~patent~~Federal ~~protection~~Republic ~~when investing in the Company. At the time~~ of ~~signing the license agreement with NIPRD in July 2002, there were not 46 patents covering NIPRISAN and Nigerian Government Officials knew or should have known this~~Nigeria.

~~There~~In ~~is no evidence that Dr. Pandey knew about this constructive fraud when he signed the license agreement in~~ July 2002 and filed SEC documents stating there were patents in 46 countries. Recently discovered Company documents, however, indicate that between July 2003 and July 2004 Dr. Pandey discovered there were not 46 patents covering NIPRISAN and failed to make this known to the ~~public. Investors~~ ~~continued to rely on the earlier SEC filings when buying and selling the common stock and when investing over $10 million in convertible debt in the~~ Company, ~~under~~formed ~~the~~Xechem ~~belief~~Pharmaceuticals ~~there~~Nigeria ~~were~~Limited ~~46 patents covering NIPRISAN.~~("Xechem

~~SIGNATURE~~Nigeria"). On July 18, 2002, the Company signed an exclusive worldwide license agreement (the “Agreement”) with the National Institute of Pharmaceutical Research and Development (Federal Ministry of Health) the Federal Republic of Nigeria, for the manufacture, marketing, distribution and sales of NIPRISAN(TM), a botanical (the “Botanical”) for the treatment of Sickle Cell Disease. The Minister of Health, A.B.C. Nwosu, signed the Agreement in his capacity as Minister of Health of Nigeria.

The Agreement stated there were “…related patents and foreign counterpart patents thereof, and totaling forty-six (46) patents world-wide….”, and the Licensor warranted that “… LICENSED PATENTS are, each and every one, valid and enforceable in their respective jurisdictions, and that LICENSOR has maintained and shall maintain the validity and enforceability of the said PATENT RIGHTS for the term of this AGREEMENT.”

Documents filed during the Bankruptcy proceedings of the Company disclosed licensed patents had been abandoned, and were no longer valid and enforceable, before the Agreement was signed on July 18, 2002, and therefore there were not “forty-six (46) patents world-wide” , as the Agreement stated, when the Agreement was signed on July 18, 2002. The Company paid licensing fees and royalty payments to the National Institute of Pharmaceutical Research and Development, and the Company invested substantial sums of money in the development of the Botanical, all under written representations contained in the Agreement signed by The Minister of Health, A.B.C. Nwosu, in his capacity as Minister of Health of Nigeria.

Item 9.01

Financial Statements and Exhibits.

(a)

Financial Statements

None

(b)

Exhibits

None

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Xechem International, Inc.
			XECHEM INTERNATIONAL, INC.
Dated: July 10, 2009	By:	/s/ Robert Swift
Date: October 17, 2011			By:	/s/ Stephen F Burg
		Chief Oversight Officer
			Name:	Stephen F Burg
			Title:	Corporate Secretary

Filing Compare · XECHEM INTERNATIONAL INC